Senestech Inc Stock Price, News & Analysis

SenesTech (NASDAQ: SNES) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after the market close. The company will host a conference call the same day at 5:00 p.m. Eastern time to discuss the results for the period ended March 31, 2025.

Investors can join the conference call by dialing (844) 308-3351 or (412) 317-5407. A live webcast will be available through the company's Investor Relations website. A teleconference replay will be accessible for seven days, while the webcast replay will remain available for 90 days in the Investor Relations section.

SenesTech (Nasdaq: SNES) has expanded the deployment of its Evolve™ Rat Birth Control solution in Chicago's Wicker Park Bucktown Special Service Area. The program, implemented by the Wicker Park Bucktown Chamber of Commerce, involves installing bait boxes in neighborhood alleys to control rat populations without using harmful toxins or poisons.

The Chicago deployment follows significant urban implementations, including a rat contraceptive pilot program approved by the New York City Council in September, as well as deployments in Boston and Baltimore. The initiative aims to protect other animals and water supplies while effectively managing rodent populations.

Alice Howe, Special Service Area N. 33 Program Manager, is overseeing the program, while SenesTech's CEO Joel Fruendt reports positive early consumption rates and plans for expanding the deployment area with a second shipment already in progress. The company has also launched an informational website for local residents and business owners.

SenesTech (NASDAQ: SNES), a leader in fertility control solutions for rodent population management, has announced its participation in the Lytham Partners 2025 Industrials & Basic Materials Investor Summit. The company will engage in a virtual fireside chat on Tuesday, April 1, 2025, at 3:00 p.m. ET.

The event will be accessible through the conference website at lythampartners.com/ibmsummit25/ or directly via lythampartners.com/ibmsummit25/snes/. A replay option will be available through the same links. Additionally, interested parties can schedule one-on-one investor meetings following the event by reaching out to Lytham Partners representatives.

SenesTech (NASDAQ: SNES) reported strong Q4 2024 financial results, with revenue increasing 70% to $501,000 compared to Q4 2023. The company achieved a 60.9% gross profit margin, up from 43.7% in Q4 2023, while reducing operating expenses by 16%. Net loss decreased to $1.3 million from $1.7 million year-over-year.

The company's Evolve™ Rat product line contributed 52% of Q4 2024 revenue, while the newly launched Evolve™ Mouse accounted for 24%. E-commerce sales grew 206%, with successful launches on major platforms including Amazon and Walmart. The company has expanded internationally into 10 countries and secured municipal programs in several U.S. cities.

SenesTech announced new optimization initiatives expected to reduce expenses by $2 million annually, lowering the revenue threshold for cash flow breakeven from $12 million to approximately $7 million. The company's cash position stood at $1.3 million as of December 31, 2024, with an additional $2 million raised in Q1 2025 through ATM facility and warrant exercises.

SenesTech (NASDAQ: SNES) has announced warrant exercise agreements that will generate approximately $1.1 million in gross proceeds. The company, specializing in fertility control solutions for rodent populations, will allow the exercise of 374,718 outstanding warrants at a reduced price of $2.90 per share, down from the original $4.35.

As part of the transaction, SenesTech will issue new unregistered short-term warrants to purchase up to 1,498,872 shares at $2.90 per share, potentially generating an additional $4.3 million if fully exercised. These new warrants will be exercisable upon stockholder approval and expire 18 months thereafter. H.C. Wainwright is serving as the exclusive placement agent, with the transaction expected to close around March 11, 2025.

SenesTech (NASDAQ: SNES) has announced it will release its fourth quarter and fiscal year 2024 financial results on Wednesday, March 12, 2025, after market close. The company will host a conference call the same day at 5:00 pm ET to discuss the results.

Investors can join the conference call by dialing (844) 308-3351 or (412) 317-5407. A live webcast will be available through the company's Investor Relations website. A teleconference replay will be accessible for seven days using replay code 7759112, while the webcast replay will remain available for 90 days on the company's investor website.

SenesTech (NASDAQ: SNES) announces expansion into New Zealand and Australia markets with its Evolve™ rodent fertility control solution. The company expects regulatory approval in New Zealand by Q3 2025, with shipments beginning in late Q2 or early Q3. Through partnership with Evicom, SenesTech aims to integrate into New Zealand's Predator Free 2050 initiative, a $4.5 billion conservation program.

The expansion targets Australia's growing rodent pest control market, currently valued at $100 million and growing 5% annually. SenesTech projects regional annual demand for Evolve to reach or exceed $500,000. The product offers a non-lethal alternative to traditional rodenticides, addressing environmental concerns while maintaining effectiveness in pest management.

SenesTech (NASDAQ: SNES) has announced a significant expansion into the warehousing and distribution sector with a multi-pallet shipment of its Evolve™ Rodent Birth Control product to a major Midwest warehousing and distribution company. The unnamed customer plans to both implement the product in their facilities and distribute it through their network.

This strategic move targets the U.S. warehousing industry, which comprises over 18 billion square feet of industrial and logistics real estate. The company's non-lethal rodent control solution addresses unique challenges in food storage facilities where traditional poisons are often unsuitable due to safety concerns.